Introduction {#s1}
============

Germ cell cancers (GCCs) are usually diagnosed between the age of 20--40 years and are the most common cancer type of young men [@pone.0071113-Oosterhuis1]. In infants and pre-pubertal adolescents, teratomas and yolk-sac tumors (Type I GCC) are detected in gonads, cranium or along the body midline. These tumors characteristically consist of tissues of all three germ layers and are generally benign in nature, with rare malignant transformation. It is assumed that the precursor cells of these tumors are primordial germ cells/gonocytes which fail to progress into spermatogonia [@pone.0071113-Schneider1];3;4\] and transform into embryonal carcinoma (EC) cells which appear at embryonic day (E) 15.5 [@pone.0071113-Pierce1]. Knowledge of the regulatory network of germ cell specification, maintenance and differentiation is required to further understand the molecular basis of this malignancy and some of the molecular key players have been determined in the past years. Specification of murine primordial germ cells (PGCs) occurs at E6.75 and is mediated by BMP signaling (BMP4/BMP8b) [@pone.0071113-LawsonK1]; [@pone.0071113-Ying1]; [@pone.0071113-Ying2], which leads to induction of *Prdm1* and *Prdm14.* PRDM1 (BLIMP1) together with PRDM14 are viewed as the key regulators since they orchestrate the re-acquisition of pluripotency and repression of the somatic program in PGCs [@pone.0071113-Ohinata1]; [@pone.0071113-Kurimoto1]; [@pone.0071113-Yamaji1]. Single cell analyses in *Blimp1* deficient PGCs suggest that the transcription factor TFAP2C is a downstream target of BLIMP1, as *Tfap2c* level was found to be dramatically reduced in *Blimp1* deficient PGCs [@pone.0071113-Kurimoto1]. TFAP2C (Tcfap2c/AP-2γ) is a member of the activator protein-2 (AP-2) family, which comprises of five closely related members, namely *Tfap2a-e*. They are characterized by a highly conserved DNA-binding and dimerization motif at the C-terminus. AP-2 transcription factors bind to DNA as functional dimers and their activation is mediated by an N-terminal transactivation domain [@pone.0071113-Eckert1]. *Tfap2c* is expressed in murine PGCs shortly after their specification from E7.25 up to E12.5 after they have migrated and colonized the genital ridges [@pone.0071113-Weber1]. After arrival in the genital ridges, PGCs initiate further differentiation indicated by downregulation of pluripotency markers *Nanog, Oct3/4, Sox2* [@pone.0071113-Yabuta1], exit of mitosis [@pone.0071113-Western1], upregulation of germ cell markers *Mutvh* and *Dazl* [@pone.0071113-Toyooka1]; [@pone.0071113-Seligman1] and epigenetic remodeling (remethylation, upregulation of *de novo* methylases) [@pone.0071113-Seki1]. Similar to *Blimp1* [@pone.0071113-Ohinata1], *Tfap2c* deficient PGCs are lost shortly after specification at E8.5. In *Tfap2c^−/−^*PGCs, germ cell markers (like *Stella/Dppa3*, *Nanos3*, *Dazl*, *Mutvh*) are downregulated and the somatic gene program is upregulated (*Hoxb1*, *Hoxa1*, *T*) resulting in loss of PGC-fate and somatic differentiation of the cells [@pone.0071113-Weber1]. In humans, TFAP2C expression is detected in fetal germ cells from week 12 to 37 of pregnancy and in a small subset of cells (gonocytes) in the infantile testes (until 4 months of postnatal age) [@pone.0071113-HoeiHansen1]. Furthermore, high levels of TFAP2C protein were observed in precursor lesions of GCC (carcinoma in situ (CIS)) and classical seminomas [@pone.0071113-HoeiHansen1]; [@pone.0071113-Pauls1].

In this study, we analyzed the consequences of lack of *Tfap2c* in PGC-like cells (PGCLCs). Global cDNA expression profiling revealed that *Tfap2c* deficiency affects cell cycle exit, epigenetic remodeling, germ cell differentiation and regulation of pluripotency. Using chromatin-immunoprecipitation (ChIP) analyses we show that *Sfrp1*, *Dmrt1*, *Nanos3*, *c-Kit*, *Cdk6*, *Cdkn1a*, *Fgf4*, *Klf4, Dnmt3b* and *Dnmt3l* are direct transcriptional target genes of TFAP2C. The data suggest that TFAP2C governs many aspects of PGC development, some of them being also involved in GCC formation. In line with this, we demonstrate that haploinsufficiency of *Tfap2c* or its target gene *Nanos3* lead to high rate of GCC in 129S2/Sv mice, resembling human pediatric germ cell tumors.

Materials and Methods {#s2}
=====================

Animals/Ethics Statement {#s2a}
------------------------

All experiments were conducted according to the German law of animal protection and in agreement with the approval of the local institutional animal care committees (Landesamt für Natur, Umwelt und Verbraucherschutz, North Rhine-Westphalia (approval ID: \#8.87-50.10.31.08.238). The experiments were conducted in accordance with the International Guiding Principles for Biomedical Research Involving Animals as announced by the Society for the Study of Reproduction.

Generation of Blimp1mVenus/Tfap2c^−/−^ ESCs {#s2b}
-------------------------------------------

The derivation of embryonic stem cells (ESCs) from blastocysts was performed by mating Blimp1mVenus (*Tg^(Prdm1-Venus1)Sait^*, MGI:3805969) [@pone.0071113-Ohinata2] with *Tfap2c^flox/flox^* (*Tfap2c^tm1Hsc^*, MGI:2176695) [@pone.0071113-Werling1] mice. ES cells were derived according to published protocols to obtain *Blimp1mVenus/Tfap2c^flox/flox^* ESCs [@pone.0071113-Kuckenberg1]. Transient transfection with a pGK-Cre plasmid resulted in Cre-mediated excision of the floxed sites leading to *Blimp1mVenus/Tfap2c^−/−^*ESCs. Genotyping of *Tfap2c* and *Blimp1mVenus* alleles was done as described previously [@pone.0071113-Ohinata2]; [@pone.0071113-Werling1].

Embryoid Body Formation {#s2c}
-----------------------

For gene expression analysis *Blimp1mVenus/Tfap2c^ctrl^* and *Blimp1mVenus/Tfap2c^−/−^*ESCs were cultured for embryoid body (EB) formation in DMEM/F12/Neurobasal media (1∶1) supplemented with Glutamax, N2-Supplement (1×), B27-Supplement (1×), L-Glutamine (1×) (all Gibco, Life Technologies, Darmstadt, Germany), BSA (2,5 mg/ml; Sigma Aldrich; Munich, Germany), ß-Mercaptoethanol (100 µM, PAA; GE Healthcare; USA), Insulin (1 mg/ml; Sigma Aldrich; Munich, Germany), PD0325901 (1 µM; Stemgent, San Diego, USA), CHIR99021 (3 µM; Stemgent, San Diego, USA) and Lif (1000 U/ml; Esgro, Merck Millipore, Darmstadt, Germany). Cells were dissociated with Accutase (PAA; GE Healthcare; USA). PGCLC differentiation was performed as described by Hayashi et al. [@pone.0071113-Hayashi1]. *Blimp1mVenus/Tfap2c^ctrl^*-PGCLCs and *StellaGFP* ESCs [@pone.0071113-Payer1] (which were differentiated into EBs for 5 days as described by Young et al. [@pone.0071113-Young1]) were used for ChIP analyses. For *StellaGFP*-PGCLC *in vitro* differentiation DMEM supplemented with GlutaMAX, Sodium Pyruvat (Gibco, Life Technologies, Darmstadt, Germany), ß-mercaptoethanol (100 µM; PAA; GE Healthcare; USA), nonessential amino acids (1×; PAA; GE Healthcare; USA); essential amino acids (1×; PAA; GE Healthcare; USA); L-Glutamine (2 mM; PAA; GE Healthcare; USA); Penicillin/Streptomycin (1×; PAA; GE Healthcare; USA); LIF (1000 U/ml; Esgro, Merck Millipore, Darmstadt, Germany); 15% ES FCS (Hyclone; Thermo Scientific; USA) and BMP4 (100 ng; R&D Systems; Wiesbaden, Germany) was used.

Fluorescence Activated Cell Sorting (FACS) {#s2d}
------------------------------------------

Embryoid bodies were washed with PBS, dissociated with Accutase (PAA; GE Healthcare; USA) and filtered through a cell strainer (40 µm, BD Biosciences, Heidelberg, Germany). Analysis was performed using FACS Aria III analytical flow cytometer (BD Biosciences, Heidelberg, Germany). All Blimp1mVenus positive cells were recorded per experiment. Data were analyzed using BD FACSDiva 6.3.1 software. Significance was calculated by 2 paired t-test. A p-value of \<0.05 was considered to be significant.

Transfection of TCam-2 Cells {#s2e}
----------------------------

siRNA mediated knockdown of TFAP2C in TCam-2 cells was performed as described by [@pone.0071113-Nettersheim1]. Scrambled and TFAP2C siRNA were obtained from Origene (TFAP2C SR304789, Origene Technologies, Rockville, USA).

Chromatin-immunoprecipitation {#s2f}
-----------------------------

Aliquots of 1×10^5^ PGCLCs were cross-linked with 1% formaldehyde for 7 min and incubated with 0.1 M glycine for 5 min at room temperature. Cells were resuspended in 200 µl SDS Lysis Buffer and sonicated for 2 cycles (5 min) and 1 cycle (2 min) (30 sec "ON"/30 sec "OFF"). Chromatin-immunoprecipitation (ChIP) experiments were performed as described in [@pone.0071113-Lim1]. For immunoprecipitation 3 µg antibody against TFAP2C (clone H77/sc-8977 X; SantaCruz, Santa Cruz, USA) and as control antibody against rabbit IgG (Merck Millipore, Darmstadt, Germany) on protein G coupled Dynabeads (Life Technologies, Darmstadt, Germany) were used. Immunoprecipitated DNA was amplified using GenomePlex® Single Cell Whole Genome Amplification Kit (WGA4) (Sigma Aldrich; Munich, Germany) according to manufacturer's protocol. Amplified ChIP DNA was subjected to qPCR using a Maxima SYBR Green/ROX (Fermentas, Thermo Scientific; USA) in a ViiA™ 7 Real-Time PCR System (Applied Biosystemş Life Technologies, Darmstadt, Germany) according to the manufacturer's specified parameters. Amplicons were normalized to the non-immunoprecipitated input DNA. Primers used for qPCR are listed in [Table S4](#pone.0071113.s006){ref-type="supplementary-material"}.

Semiquantitative RT-PCR {#s2g}
-----------------------

Total RNA from ESCs and sorted PGC-like cells were isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). First-strand cDNA were synthesized using RevertAid Premium reverse transcriptase (Fermentas, Thermo Scientific; USA). RNA from gonads was extracted using the Nucleo Spin FFPE RNA Kit (Macherey & Nagel, Düren, Germany); 100 ng was used for cDNA synthesis (SuperScriptIII; Invitrogen, Karlsruhe, Germany). RT-PCR-primers are listed in [Table S5](#pone.0071113.s007){ref-type="supplementary-material"}.

qRT-PCR {#s2h}
-------

RNA from PGCLCs and gonads was isolated using RNeasy Mini/Micro Kit (Qiagen, Hilden, Germany), respectively. Total RNA from TCam-2 cells was extracted by Trizol (Sigma Aldrich; Munich, Germany) according to manufactureŕs instructions. For amplification of PGCLCs, gonadal and TCam-2 mRNA, SYBR GreenER Reagent Mix (Invitrogen, Karlsbad, Germany)/Maxima SYBR Green/ROX (Fermentas, Thermo Scientific; USA) was used. Housekeeping genes *βActin* and *Gapdh* were used for data normalization. The experiments were performed in biological triplicates. Primer sequences for qRT-PCR are given in [Table S6](#pone.0071113.s008){ref-type="supplementary-material"}.

Transcriptome Microarray Analysis {#s2i}
---------------------------------

For the microarray experiments GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) were used. RNA was extracted from ESCs and sorted PGCLCs using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA quality was tested using the Agilent 2100 Bioanalyzer (Agilent Technologies, Böblingen, Germany). For the Affymetrix array, 100 ng of total RNA were used. The arrays were washed and stained according to the manufacturer's recommendations and scanned in a GeneChip scanner 3000 (Affymetrix, Santa Clara, CA, USA). The normalization was calculated with the RMA (Robust Multi-array Analysis) algorithm [@pone.0071113-IrizarryR1]. Data post-processing and graphics were performed with in-house developed functions in Matlab. Hierarchical clustering of genes and samples was performed with one minus correlation metric and the unweighted average distance (UPGMA) (also known as group average) linkage method. The gene ontology analysis based on AMIGO gene ontology database [@pone.0071113-Ashburner1]. The significance of the gene ontology terms of the differentially expressed genes was analyzed using an enrichment approach based on the hypergeometric distribution. All sets of gene ontology terms were backpropagated from the final term appearing in the gene annotation until the root term of each ontology. The significance (p-value) of the gene ontology terms enrichment was calculated using the hypergeometric distribution. The multitest effect influence was corrected through controlling the false discovery rate using the Benjamini-Hochberg correction at a significance level α = 0.05. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE45941.

Laser Microdissection {#s2j}
---------------------

Paraffin-embedded tissue was sectioned to 10 µm thickness and mounted on P.A.L.M. Frame slides (Carl-Zeiss Micro Imaging, Göttingen, Germany) and stained with SSEA-1 antibody (R&D Systems, Minneapolis, USA). SSEA-1 positive areas were dissected using P.A.L.M. Microlaser Technology (Carl-Zeiss Micro Imaging, Göttingen, Germany). Dissected tissue was collected in lysis buffer (1 mM EDTA pH 8, 10 mM Tris-HCl pH 8, 0.5% Tween20, 100 mg/ml proteinase K) and incubated at 37°C for 3 hrs, heated to 85°C for 10 min. DNA was extracted with QiaAmp DNA Micro Kit (Qiagen, Hilden, Germany). RNA was extracted with Nucleo Spin FFPE RNA Kit (Macherey & Nagel, Düren, Germany).

Histology and Immunohistochemistry {#s2k}
----------------------------------

Sections and cells were fixed and stained as described by Weber et al. [@pone.0071113-Weber1]. The following antibodies were used: TFAP2C (1∶300--1∶500, SantaCruz, Santa Cruz, USA), OCT3/4 (1∶100, SantaCruz, Santa Cruz, USA), SSEA1 (1∶100, R&D Systems, Minneapolis, USA), anti-rabbit biotinylated (1∶500; DAKO, Hamburg, Germany), anti-rat biotinylated (1∶200; DAKO, Hamburg, Germany), anti-rabbit Alexa fluor 594 (1∶1000; Life Technologies, Darmstadt, Germany); anti-mouse Alexa fluor 488 (1∶1000; Life Technologies, Darmstadt, Germany). Nuclei were stained using 1∶500 33342 Hoechst (1 mg/ml; Life Technologies, Darmstadt, Germany).

Results {#s3}
=======

*Tfap2c* Deficient ESCs Generate Less PGCLCs {#s3a}
--------------------------------------------

In order to analyze the molecular consequences of *Tfap2c* deficiency in PGCs we took advantage of protocols allowing PGCLC derivation from embryonic stem cells through an epiblast-like cell (EpiLC) intermediate [@pone.0071113-Hayashi1]. *Blimp1mVenus* reporter mice [@pone.0071113-Ohinata2] were bred into the *Tfap2c^flox/flox^* background [@pone.0071113-Werling1] and two *Blimp1mVenus/Tfap2c^flox/flox^* embryonic stem cell (ESC) lines were established. Next, the ESC-lines were transiently transfected with a plasmid encoding the Cre-Protein (pgk-Cre) mediating the deletion of the *Tfap2c^flox/flox^* alleles resulting in *Blimp1mVenus/Tfap2c^−/−^* ESCs (\#1-*Tfap2c^−/−^* and \#2-*Tfap2c^−/−^*) ([Fig. S1](#pone.0071113.s001){ref-type="supplementary-material"} A, B, C). For all following experiments, the parental *Blimp1mVenus/Tfap2c^flox/flox^* ESC-lines served as control (ctrl). Under serum and feeder-free conditions ESCs were differentiated for two days into EpiLCs, which display a flattened epithelial-like structure ([Fig. S2](#pone.0071113.s002){ref-type="supplementary-material"} A). The expression of marker genes in \#1-*ctrl*, \#1-*Tfap2c^−/−^*, \#2-*ctrl* and \#2-*Tfap2c^−/−^* cells was analyzed by semiquantitative RT-PCR to address the question, whether loss of TFAP2C affects differentiation from ESCs to EpiLCs. Upon differentiation into EpiLCs, marker genes for ESCs, *Klf4* and *Prdm14*, were downregulated and epiblast associated genes *Fgf5* and *Dnmt3b* were upregulated ([Fig. S2 B](#pone.0071113.s002){ref-type="supplementary-material"}). The results suggest that the generation of EpiLCs is not affected by lack of TFAP2C.

Next, PGCLC differentiation was induced by cultivating EpiLCs in medium supplemented with BMP4, BMP8b, SCF, LIF and EGF [@pone.0071113-Hayashi1]. Induction of the *Blimp1mVenus* reporter indicated the generation of PGCLCs, which were quantified using fluorescence activated cell sorting (FACS) ([Fig. S1](#pone.0071113.s001){ref-type="supplementary-material"} C/S2 C). Using *Tfap2c^−/−^* ESC-lines, we obtained less Blimp1mVenus positive PGCLCs (\#1∶9.3% vs. 2.7% (significant); \#2∶3% vs. 1.5% (non-significant)) ([Fig. S2 D](#pone.0071113.s002){ref-type="supplementary-material"}). RT-PCR demonstrated that lack of *Tfap2c* did not affect the expression of the early germ cell marker *Prdm14*, but lead to a reduction of late markers (*Stella, Nanos3*) ([Fig. S2 E](#pone.0071113.s002){ref-type="supplementary-material"}). Expression of *Prdm14* and the *Blimp1mVenus* reporter indicate that PGCLCs are specified in the absence of TFAP2C. However, the reduction of the number of PGCLCs strongly suggests a role of TFAP2C in the maintenance of the PGC-fate. The fact, that the expression of late germ cells markers is impaired argues against the possibility that the *Tfap2c^−/−^*PGCLCs undergo premature differentiation.

Transcriptome Analysis of *Tfap2c* Deficient ESCs and *in vitro* Differentiated PGCLCs {#s3b}
--------------------------------------------------------------------------------------

To gain insight into the consequences of lack of *Tfap2c* on a genome-wide level, gene expression analysis using ESCs and PGCLCs (\#1-*ctrl;* \#1-*Tfap2c^−/−^*; \#2-*ctrl* and \#2-*Tfap2c^−/−^*) was performed with Affymetrix Mouse 430 2.0 microarrays. Hierarchical clustering showed that *Tfap2c^−/−^*PGCLCs cluster close together and distant from control samples indicating the high similarity of gene expression profiles within the *Tfap2c^−/−^* and *ctrl* pairs ([Fig. 1](#pone-0071113-g001){ref-type="fig"} A). Heat map shows differentially expressed transcripts between the *Tfap2c^−/−^* and *ctrl* PGCLCs ([Fig. 1](#pone-0071113-g001){ref-type="fig"} B). Scatter plotting of *Tfap2c^−/−^* vs. *ctrl* PGCLCs identified 455 significantly deregulated genes (Fold-change \>1.5 in log2 scale) ([Fig. 1](#pone-0071113-g001){ref-type="fig"} C; [Table S1](#pone.0071113.s003){ref-type="supplementary-material"}). Of note, TFAP2C has only moderate effects in ESCs (albeit *Tfap2c* is expressed in 10--15% of ESCs) [@pone.0071113-Kuckenberg1] as indicated by hierarchical clustering, heat mapping and scatter plotting ([Fig. 1](#pone-0071113-g001){ref-type="fig"} A, B, D). In ESCs, only 26 genes were deregulated after loss of TFAP2C ([Table S2](#pone.0071113.s004){ref-type="supplementary-material"}). Comparing the PGCLC with ESC datasets revealed an overlap of 13 genes ([Fig. 1](#pone-0071113-g001){ref-type="fig"} E; [Table S3](#pone.0071113.s005){ref-type="supplementary-material"}). These results indicate that TFAP2C controls a diverse set of genes in ESCs and PGCLCs and that the lack of this protein in PGCLCs affects the expression of far more genes compared to ESCs.

![Genes regulated in PGCLCs and ESCs by TFAP2C.\
Affymetrix microarray gene expression analysis performed with RNA extracted from \#1-*ctrl*; \#1-*Tfap2c^−/−^* and \#2-*ctrl*; \#2-*Tfap2c^−/−^* ESCs and PGCLCs. (A) Hierarchical clustering. The red bars cluster the ESCs, green bars the *Tfap2c^−/−^*PGCLCs and blue bars ctrl PGCLCs, respectively. The shorter the horizontal bar that connects two branches the closer are the populations. (B) Heat map was performed with the probes whose range or variation across all samples was at least 3. Color bar on top codifies the gene expression in log2 scale. Red and blue indicate higher and lower relative expression. (C-D) Pairwise scatter plot of global gene expression in ctrl versus *Tfap2c^−/−^*PGCLCs (C) and ESCs (D). Black lines indicate 1.5 fold-change in log2 scale of gene expression levels between paired PGCLCs and ESCs. Color bars on the side display the scattering density with light blue indicating lower and blue higher scatter density. Genes upregulated in *Tfap2c^−/−^* samples are shown as red dots; genes downregulated are shown as green dots. R^2^ = Fisher's correlation coefficient. (E) Venn diagram; in PGCLCs 455 genes are deregulated; in ESCs 26 genes are deregulated. The intersection part show the commonly deregulated genes (n = 13) by TFAP2C in PGCLCs and ESCs (Fold-change \>1.5 in log2 scale).](pone.0071113.g001){#pone-0071113-g001}

Next we performed gene ontology analysis [@pone.0071113-Ashburner1] ([Data S1](#pone.0071113.s010){ref-type="supplementary-material"}) and categorized the genes deregulated in *Tfap2c^−/−^*PGCLCs in relation to their biological function. Here, it became evident that in *Tfap2c^−/−^*PGCLCs many genes associated with somatic differentiation (category I) are upregulated, whereas genes associated with germ cell maintenance and maturation (category II) are downregulated ([Table 1](#pone-0071113-t001){ref-type="table"}). Of note, we also included few genes in [Table 1](#pone-0071113-t001){ref-type="table"} with relevance to the respective category displaying a fold-change rate below our initial cutoff (≤1.5 in log2 scale, see [Table 1](#pone-0071113-t001){ref-type="table"}). These data suggest an impairment of PGC to gonocyte progression and derepression of somatic differentiation upon loss of TFAP2C. These results confirm earlier data, where markers indicative for somatic differentiation were induced in *Tfap2c* deficient EBs [@pone.0071113-Weber1]. In addition, we found upregulation of genes associated with cell cycle regulation (category III), pluripotency (category IV) and epigenetic modification (category V) in *Tfap2c^−/−^*PGCLCs. The data indicate that in migrating PGCs, TFAP2C represses the cell cycle, pluripotency program and DNA methylation.

10.1371/journal.pone.0071113.t001

###### Categorized deregulated genes in *Tfap2^−/−^*PGCLCs based on gene ontology analysis.

![](pone.0071113.t001){#pone-0071113-t001-1}

  Category               Upregulatedgenes    FC                       Function                      Downregulated genes    FC                        Function
  --------------------- ------------------ ------ ------------------------------------------------ --------------------- ------- -------------------------------------------------
  **I:**                    **Bcl11a**      1.93          leukemogenesis and hematopoiesis               **Gata2**        −1.87                    hematopoiesis
  **Somatic**               **Cited2**      1.87                  CNS development                        **Lhx1**         −1.59                  mesodem formation
  **differentiation**        **Chd7**       1.67                  CNS development                        **Slit2**        −2.34                    neurogenesis
                             **Cobl**       2.43                neural tube closure                     **Kctd15**        −3.20           inhibit neural crest formation
                             **Ehna**       2.01                neural tube closure                   **Pecam1/CD31**     −1.50                mesoderm development
                            **Epha2**       1.53              neural tube development                                            
                             **Gbx2**       2.36            gastrulation-brain specific                                          
                             **Gli2**       3.48              neural tube development                                            
                             **Hck**        2.83              hemopoietic cell kinase                                            
                             **Hhex**       1.52     hematopoietically expressed homeobox gene                                   
                            **Hoxa5**       1.97          mammary gland- lung development                                        
                              Hoxa1         1.13   central nervous system neuron differentiation                                 
                              Hoxa3         1.13         cartilage- and thymus development                                       
                              Hoxb1         1.03                  CNS development                                                
                            **Mtap1b**      1.70                  CNS development                                                
                            **Ncam1**       2.42               neuron-neuron adhesion                                            
                             **Nefl**       3.56                    neurogenesis                                                 
                           **Neurod1**      1.57                    neurogenesis                                                 
                            **Pou4f2**      1.58                 expressed in brain                                              
                             **Pten**       1.63                  CNS development                                                
                            **Robo1**       1.79                    neurogenesis                                                 
                            **Sfrp1**       3.12        neural tube closure and development                                      
                            **Sfrp2**       1.66              neural tube development                                            
                           **Smarca1**      2.06     neuron differentiation, brain development                                   
                            **Tcf7l2**      2.56              neural tube development                                            
                             **Zic2**       3.71        CNS development; neural tube closure                                     
                             **Zic5**       3.14                neural tube closure                                              
  **II:**                   **Cited2**      1.87                 sex determination                       **Aurkc**        −2.06           key regulator mitosis; meiosis
  **Germ cell**              **Pten**       1.63            tumor suppressor; apoptosis                   **Bik**         −2.20             spermatogenesis, apoptosis
  **maintenance**          **Sprink3**      2.54       inhibits calcium uptake in spermatozoa              Cdk16          −1.00            required for spermatogenesis
  **and**                                                                                              **Ceacam10**       −2.98                sperm surface protein
  **maturation**                                                                                         **Chdh**         −4.80             localized in mitochondrial
                                                                                                         **Cxcr4**        −1.94                 germ cell migration
                                                                                                           Dazl           −1.40           gametogenesis; spermatogenesis
                                                                                                         **Dmrt1**        −2.68     male sex determination and differentiation
                                                                                                          **Hk1**         −3.04   expressed in meiosis and postmeiotic germ cells
                                                                                                        **Immp2l**        −1.57                   spermatogenesis
                                                                                                          **Kit**         −1.91     cell survival, migration and proliferation
                                                                                                      **Phf13/Spoc1**     −1.85                   spermatogenesis
                                                                                                         **Rhox5**        −4.29          spermatogenesis, sperm maturation
                                                                                                        **Rhox4a**        −2.70            in fetal germ cells expressed
                                                                                                         **Rhox6**        −6.11           germ cell lineage determination
                                                                                                      **Rhox9/Psx2**      −5.59                      oogenesis
                                                                                                         **Sept4**        −1.63   sperm capacitation; mitochondrion organization
                                                                                                        **Slco4c1**       −2.32                  sperm maturation
                                                                                                         **Spa17**        −2.30                sperm surface protein
                                                                                                     **Stella/Dppa3**     −4.27                PGC specific protein
                                                                                                         **Stk31**        −2.40         male germ cell specific expression
                                                                                                          **Tes**         −2.04          cell adhesion, cell proliferation
  **III:**                  **Ccnd1**       2.33              interacts with Cdk4/Cdk6                   **Urgcp**        −3.17                 regulation of Ccnd1
  **Cell cycle**            **Ccnt2**       1.88                interacts with Cdk9                                              
                            **Cdc14a**      1.57             cell cycle; cell division                                           
                             **Cdk6**       1.50              promotes G1/S transition                                           
                               Cdk7         1.17             cell cycle; cell division                                           
                            Cdkn1a/p21      1.02      bind and inhibit cyclin-dependent kinase                                   
                             **Plk2**       1.68         involved in G1/S phase transition                                       
                           **S100a10**      2.15     cell cycle progression and differentiation                                  
  **IV:**                    **Eras**       3.52          maintenance of ESC pluripotency                                        
  **Pluripotency**           **Fgf4**       2.94   regulation cell proliferation, differentiation                                
                              FoxD3         1.03        early direct response gene of Oct3/4                                     
                             **Gbx2**       2.36       cell pluripotency and differentiation                                     
                             **Jam2**       2.47        early direct response gene of Oct3/4                                     
                             **Klf4**       2.22          maintenance of ESC pluripotency                                        
                             **Msi2**       2.31      RNA binding protein; self-renewal of ESC                                   
                            **Nr0b1**       1.62          maintenance of ESC pluripotency                                        
                              Tdgf1         1.36        early direct response gene of Oct3/4                                     
  **V:**                      Dnmt3b        1.34          genome-wide de novo methylation                **Pcgf5**        −2.40     chromatin remodeling; histone modification
  **Epigenetics**           **Dnmt3l**      3.21         DNA methyltransferase like enzyme                                       
                          Smarca6/Hells     1.09     de novo or maintenance of DNA methylation                                   
                             **Mbd2**       1.54      recruits Hdacs and Dnmts; gene silencing                                   
                               Tet2         1.27             conversion of 5mC to 5hmC                                           
                              Uhrf1         1.45         major role in the G1/S transition                                       

bold: genes with fold-change \>1.5 in log2 scale; regular: genes with fold-change ≤1.5 in log2 scale.

Subsequently, differential expression seen in the cDNA-microarray of selected marker genes was validated using qRT-PCR in PGCLCs ([Fig. 2](#pone-0071113-g002){ref-type="fig"} A) (downregulated: *Nanos3* (−4.78), *Rhox5* (−4.26), *Stella* (−3.84), *Dmrt1* (−3.07), *c-Kit* (−2.78) and *Dazl* (−0.88) and upregulated: *Fgf4* (4.84), *Dnmt3l* (3.79), *Ccnd1* (3.36), *Dnmt3b* (2.07) *and Klf4* (1.95) \[fold-changes in log2 scale\]). Furthermore, expression of several markers was determined after siRNA mediated knockdown of TFAP2C in the human seminoma-like cell line TCam-2 [@pone.0071113-Eckert2] ([Fig. 2](#pone-0071113-g002){ref-type="fig"} B). Here, after reduction of TFAP2C (to ∼30% compared to the control level) *c-KIT* (−2.22) and *DMRT1* (−1.58) were downregulated and *CCND1* (1.60), *SOX2* (1.34), *DNMT3L* (0.98), *HOXA5* (0.88), and *DNMT3B* (0.39) were upregulated (all fold-changes in log2 scale). So, in both systems all selected genes were deregulated in agreement with the array analysis. This suggests a conserved function of TFAP2C/Tfap2c in humans and mice.

![Validation of cDNA microarray data.\
(A) Quantitative RT-PCR of a subset of markers with RNA isolated from ctrl and *Tfap2c^−/−^*PGCLCs. Expression levels were normalized to *βActin* and expression level of *ctrl* PGCLCs were set to 1. qRT-PCR was performed in biological triplicates. Error bars indicate standard deviation. (B) Quantitative RT-PCR of a subset of markers with RNA isolated from TCam-2 cells after siRNA mediated knockdown of TFAP2C. Expression levels were normalized to GAPDH and expression levels of scrambled-siRNA-transfection were set to 1. qRT-PCR was performed in biological triplicate. Error bars indicate standard deviation. (C) ChIP/qPCR analysis for Tfap2c was performed with four biological replicates of PGCLCs. The qPCR results were calculated with the percentage input method and ChIP analyses with IgG antibody served as control and were set to 1. Error bars indicate standard deviation. ChIP analysis demonstrates increased binding of TFAP2C at indicated loci. (A) -- (C) Marker genes were grouped in categories: somatic differentiation (category I), germ cell maintenance and maturation (category II), cell cycle regulation (category III), pluripotency (category IV) and epigenetic modification (category V).](pone.0071113.g002){#pone-0071113-g002}

ChIP Analysis Reveals Direct Transcriptional Targets {#s3c}
----------------------------------------------------

To evaluate direct binding of TFAP2C to promotor regions of deregulated genes we performed TFAP2C specific ChIP-analysis using PGCLCs derived from *Stella-GFP* ESCs [@pone.0071113-Payer1] and *Blimp1mVenus/Tfap2c^ctrl^* ESCs. Putative TFAP2C binding sites identified by the rVista algorithm (based on TRANSFAC) [@pone.0071113-Ovcharenko1] (sequence information [Table S4](#pone.0071113.s006){ref-type="supplementary-material"}) in genomic regions of *Sfrp1, Dmrt1*, *Nanos3*, *c-Kit*, *Cdk6*, *Cdkn1a*, *Fgf4*, *Klf4*, *Dnmt3b* and *Dnmt3l* were enriched for TFAP2C protein (vs. IgG control) ([Fig. 2](#pone-0071113-g002){ref-type="fig"} C), implicating those genes as direct target genes of TFAP2C.

Male Mice Heterozygous for the *Tfap2c* Deletion Develop Teratomas {#s3d}
------------------------------------------------------------------

Our analyses revealed, that TFAP2C is not only involved in suppression of the somatic program but also controls cell cycle, epigenetic modifications and pluripotency. Since these pathways are discussed to be deregulated in GCC, we wondered whether reduction of *Tfap2c* could contribute to the initiation of these tumors. The *Tfap2c^tm1Hsc^* (MGI: 93391) allele [@pone.0071113-Werling1] was bred into the 129S2/Sv genetic background and screened for effects of haploinsufficiency. To determine whether loss of one allele of *Tfap2c* affected the overall levels of *Tfap2c*-mRNA, E12.5 genital ridges of control and *Tfap2c^+/−^* embryos were dissected, RNA isolated and qRT-PCR analysis performed. Deletion of one *Tfap2c*-allele leads to reduction of *Tfap2c*-mRNA ([Fig. 3](#pone-0071113-g003){ref-type="fig"} A) and to upregulation of the direct target *Cdkn1a*/*p21* ([Fig. 3](#pone-0071113-g003){ref-type="fig"} A). Starting from the seventh generation in 129S2/Sv 82% (n = 51) of all heterozygous males developed testicular tumors ([Fig. 3](#pone-0071113-g003){ref-type="fig"} B) (35% presented as bilateral cases), whereas wildtype littermates (n = 22) remained tumor-free. Tumors presented as teratomas ([Fig. 3](#pone-0071113-g003){ref-type="fig"} C) and displayed a variety of tissues like immature glia ([Fig. 3](#pone-0071113-g003){ref-type="fig"} D) and mature cartilage ([Fig. 3](#pone-0071113-g003){ref-type="fig"} E), muscle ([Fig. 3](#pone-0071113-g003){ref-type="fig"} E), respiratory epithelium ([Fig. 3](#pone-0071113-g003){ref-type="fig"} F) as well as squamous epithelium ([Fig. 3](#pone-0071113-g003){ref-type="fig"} G). Of note, the tumors did not have a negative effect on life expectancy of affected animals, as selected mice were observed for over 1.5 years without apparent impairment of their general well-being.

![Teratoma development in *Tfap2c* heterozygous mice in 129S2/Sv genetic background.\
(A) Quantitative RT-PCR with RNA isolated from E12.5 genital ridges of wt and *Tfap2c^+/−^* embryos was performed. Expression levels of *Tfap2c* and *p21* were normalized to *Gapdh*. qRT-PCR was performed in biological duplicates. Error bars indicate standard deviation. (B) Percentage of total tumor incidence in *Tfap2c* heterozygous 129S2/Sv male mice. The seventh generation in 129S2/Sv shows 82% (n = 51) testicular tumors. Red bar: bilateral cases (35%), blue bar: unilateral tumors (47%). (C) Gross pathology of testicular teratoma in *Tfap2c^+/−^* male mice. (D--G) HE-staining of testicular teratomas of 3--6 month old mice. Tumors show immature glia (D), mature cartilage, muscle (E), respiratory epithelium (F) and squamous epithelium (G). Scale bars: 200 µm.](pone.0071113.g003){#pone-0071113-g003}

Pluripotency is Retained in Foci of *Tfap2c* Heterozygous Testes {#s3e}
----------------------------------------------------------------

Tumors were reminiscent of early childhood germ cell cancer (Type I) in humans. These tumors initiate early during germ cell development and are characterized by failure of PGCs to downregulate pluripotency markers. The lesions represent hallmarks of embryonal carcinomas [@pone.0071113-Oosterhuis1]. Here, testes of E15.5 and E16.5 *Tfap2c^+/−^* embryos were dissected, paraffin embedded and sectioned. Immunohistochemical staining of *Tfap2c^+/−^* gonads revealed foci of cells which maintain strong SSEA1 ([Fig. 4](#pone-0071113-g004){ref-type="fig"} A) and OCT3/4 ([Fig. 4](#pone-0071113-g004){ref-type="fig"} B) protein levels. The cells of these foci were still localized within the confines of the seminiferous tubule at this time point. Serial sections suggest that OCT3/4 positive foci were negative for TFAP2C ([Fig. 4](#pone-0071113-g004){ref-type="fig"} C). SSEA-1 positive foci of E16.5 testes were micro-dissected and subjected to RT-PCR and adjacent (SSEA-1 negative) testes tissue served as control. In SSEA1-positive foci *Nanog* and *Sox2* mRNA was detectable ([Fig. 4](#pone-0071113-g004){ref-type="fig"} D). The fact, that pluripotency genes are expressed and cells within the foci possess large, highly condensated nuclei as well as clearly visible nucleoli ([Fig. 4](#pone-0071113-g004){ref-type="fig"} B) indicate that these cells resemble embryonal carcinoma (EC) cells [@pone.0071113-Rivers1]. The absence of *c-Kit* expression further corroborates the EC-like nature of this lesion ([Fig. 4](#pone-0071113-g004){ref-type="fig"} D).

![Pluripotency maintaining and differentiation block show EC like nature of lesion.\
(A--C) IHC staining of E16.5 embryonal testis. (A) SSEA1, (B) OCT3/4 and (C) TFAP2C. Scale bars: 50 µm. (B) Black arrow show cells with large, highly condensated nuclei as well as clearly visible nucleoli. (D) RT-PCR from RNA of microdissected SSEA-1 positive foci of E16.5 testes detecting *Nanog*, *Sox2* and *c-Kit*. Comparison of microdissected SSEA-1 positive tissue (T) and SSEA-1 negative tissue (wt). *Gapdh* served as control.](pone.0071113.g004){#pone-0071113-g004}

Teratoma Development in Male Mice Heterozygous for *Nanos3* {#s3f}
-----------------------------------------------------------

Since we identified *Nanos3* as a direct transcriptional target of TFAP2C we addressed the question, whether *Nanos3* heterozygous mice also develop tumors. Therefore, we bred the *Nanos3*-Cre knock-in allele (*Nanos3^tm2.1(cre)Ysa^*, MGI:4358405), which represents a null allele, [@pone.0071113-Suzuki1] into the 129S2/Sv genetic background. Interestingly, from the fourth generation in 129S2/Sv 45% of *Nanos3* heterozygous males showed teratoma formation (n = 20), with 5% showing bilateral tumors ([Fig. 5](#pone-0071113-g005){ref-type="fig"} A), whereas control animals (n = 17) remained tumor-free. The histology of teratomas found in *Nanos3* heterozygous animals is comparable to those of *Tfap2c* heterozygous mice ([Fig. 5](#pone-0071113-g005){ref-type="fig"} B mesoderm; [Fig. 5](#pone-0071113-g005){ref-type="fig"} C ectoderm; [Fig. 5](#pone-0071113-g005){ref-type="fig"} D endoderm). These data suggest that teratoma susceptibility mediated by *Tfap2c* in 129S2/Sv genetic background is at least in part due to reduction of *Nanos3*. However, tumor incidence in *Nanos3* heterozygous mice was lower and tumor progression was slower compared to *Tfap2c* heterozygous animals, arguing for additional targets of TFAP2C involved in GCC pathogenesis.

![Teratoma development in *Nanos3* heterozygous mice in 129S2/Sv genetic background.\
(A) Percentage of total tumor incidence in *Nanos3* heterozygous 129S2/Sv male mice. 45% (n = 20) showed testicular tumors. Red bar: bilateral cases (5%); blue bar: unilateral cases (40%). Testes of control (wt) and *Nanos3* heterozygous (cre/+) mice (inset in A). (B--D) HE-staining of testicular teratomas of 4--8 month old mice. Tumors show tissues of all three germ layers: muscle (B), squamous epithelium (C) and respiratory epithelium (D). Scale bars: 50 µm.](pone.0071113.g005){#pone-0071113-g005}

Discussion {#s4}
==========

In this study, we analyzed the network of genes regulated by TFAP2C during germ cell development. Using an *in vitro* PGC differentiation protocol we observed deregulation of genes controlling cell cycle, somatic differentiation, epigenetic modification, pluripotency and germ cell maintenance and maturation upon loss of *Tfap2c*. ChIP analysis indicates direct binding of TFAP2C to *Sfrp1, Dmrt1*, *Nanos3*, *c-Kit*, *Cdk6*, *Cdkn1a*, *Fgf4*, *Klf4*, *Dnmt3b* and *Dnmt3l*. Since some of the genes deregulated upon loss of *Tfap2c* are known to induce GCC in mice, we bred the *Tfap2c* mutation onto the 129S2/Sv genetic background. We demonstrate that reduction of TFAP2C protein level leads to persisting expression of pluripotency and cell cycle markers in foci representing precursor lesions. Consequently, incidence of GCC increases up to 85% in *Tfap2c^+/−^* males. Tumor susceptibility seems at least in part to be mediated by the TFAP2C target gene *Nanos3* since *Nanos3* heterozygous mice also develop GCC.

The microarray analysis identified a set of 455 deregulated genes in *Tfap2c^−/−^*PGCLCs compared to the control. Interestingly, the deregulated genes in *Tfap2c^−/−^*PGCLCs could be categorized in five groups representing diverse biological functions; somatic differentiation (category I), germ cell maintenance and maturation (category II), cell cycle (category III), pluripotency (category IV) and epigenetics (category V). In addition, ChIP analyses demonstrated that TFAP2C binds to regulatory elements of genes of all these categories. Thus, aside from the role as inhibitor of somatic differentiation [@pone.0071113-Weber1], [@pone.0071113-Schfer1], TFAP2C seems to orchestrate all aspects of germ cell development instead of controlling only one category which, after deregulation would affect all others as a secondary effect.

Genes related to neural tube development/closure and central nervous system development are the GO terms significantly enriched in *Tfap2c^−/−^*PGCLCs. Interestingly, we observed that tumors in *Tfap2c^+/−^* and *Nanos3^+/−^* testes predominantly consist of undifferentiated neuronal tissue (glia cells). In general, Stevens described that teratomas induced by grafting genital ridges consist predominantly of neural tissue [@pone.0071113-Stevens1]. This suggests that TFAP2C specifically inhibits neural tube development/closure and central nervous system development during germ cell development. Here, the direct transcriptional target *Sfrp1* (Secreted frizzled-related protein 1) might be involved. It acts by antagonizing BMP-signaling in the caudal neural tube, resulting in neural tube closure defects [@pone.0071113-Misra1]. This further strengthens the notion, that loss of TFAP2C leads to derepression of somatic programs, specially neuronal cell fate, and loss of germ cells in *Tfap2c* knockout mice [@pone.0071113-Weber1].

In addition, loss of TFAP2C severely impairs the expression of genes involved in germ cell maintenance and maturation such as *Stella*, *Dazl*, *Immp2l*, *Rhox4a*, *Rhox5*, *Rhox6*, *Rhox9*, *Dmrt1*, *c-Kit*, *Cxcr4* and *Nanos3*. Among them, *Dmrt1*, *c-Kit* and *Nanos3* are direct target genes as determined by ChIP analyses. These data indicate that the lack of germ cell maturation markers is not simply a consequence of the derepressed somatic program. TFAP2C directly orchestrates the expression of the genes relevant for maintenance and maturation of PGCs/gonocytes up to E12.5, the last day expression of *Tfap2c* can be detected [@pone.0071113-Weber1].

Lack of TFAP2C led to upregulation of cell cycle and pluripotency markers as well as epigenetic regulators. This indicates a role of TFAP2C to retain the capacity of germ cells to repress pluripotency, controlling the cell cycle and epigenetic reprogramming in the germ line. Here, *Cdk6*, *Cdkn1a/p21*, *Fgf4*, *Klf4*, *Dnmt3b* and *Dnmt3l* could be shown to be direct TFAP2C targets, demonstrating that TFAP2C acts as a repressor for these genes. Upon loss of TFAP2C, cell cycle control genes such as *Ccnd1* and *Cdk6* are upregulated. *Ccnd1* (*Cyclin D1*) is expressed in proliferating gonocytes and spermatogonia, suggesting a role for *Ccnd1* in spermatogonial proliferation [@pone.0071113-Beumer1]. *Ccnd1* expression is downregulated at E16.5. Interestingly, the percentage of germ cells, which continue to express *Ccnd1* correlates with the risk of the respective mouse strain to develop teratoma [@pone.0071113-Heaney1]. It is known, that upregulation of *Ccnd1* and its partner molecule *Cdk6* lead to phosphorylation and inactivation of the retinoblastoma gene product (pRB), inducing expression of genes necessary for G1 to S-phase transit [@pone.0071113-Deshpande1]. Furthermore, ectopic expression of *Ccnd1* is sufficient to promote tumor formation by mediating growth factor independence and forces quiescent cells to reenter the cell cycle [@pone.0071113-Deshpande1], [@pone.0071113-MusgroveE1]. Of note, a rapid progression from the G1 to S phase of the cell cycle facilitates the maintenance of pluripotency [@pone.0071113-FilipczykA1], [@pone.0071113-Singh1]. Hence, we believe that *Tfap2c^−/−^* germ cells might fail to initiate the mitotic arrest and as a consequence do not differentiate further into gonocytes. Interestingly, the direct transcriptional target *Cdkn1a/p21* is upregulated in *Tfap2c^−/−^*PGCLCs and heterozygous E12.5 genital ridges. Direct binding to and repression of *p21* has been described before using MCF-7 breast cancer cells [@pone.0071113-Williams1]. While upregulation of the cell cycle repressor *p21* seems counterintuitive with regard to the above reported upregulation of *Ccnd1/Cdk6*, it has to be noted that p21 is not only associated with cell cycle arrest [@pone.0071113-Deng1], [@pone.0071113-Iii1], [@pone.0071113-OgryzkoV1] but also described as a regulator of p53-dependent and p53-independent apoptosis [@pone.0071113-Helt1], [@pone.0071113-Javelaud1]. Using *Dead End* ^−/−^ (*Dnd1^−/−^*) mice, testicular tumors were observed after repression of Bax-mediated apoptosis [@pone.0071113-Cook1]. Here, we speculate that *Tfap2c^+/−^* germ cells are less prone to apoptosis due to elevated level of *p21*.

Loss of TFAP2C caused upregulation of the pluripotency associated genes *Eras*, *Fgf4*, *Klf4* and *Nr0b1*. *Fgf4* and *Klf4* are direct transcriptional targets. In addition, it has been reported, that loss of the TFAP2C target gene *Dmrt1* leads to upregulation of pluripotency markers *Sox2*, *Nanog*, *Oct3/4* and *E-cadherin* in testes of E13.5 mice. *Sox2* is a direct transcriptional target of DMRT1 [@pone.0071113-Krentz1]. In addition, we found three OCT3/4 dependent genes [@pone.0071113-SharovA1] *Jam2*, *FoxD3* and *Tdgf1* upregulated in *Tfap2c^−/−^*PGCLCs. Interestingly, expression of *Eras* (*ES-expressing ras*) a gene related to teratoma formation in ESCs [@pone.0071113-Takahashi1] was also upregulated. Again, such an upregulation is also found upon deletion of *Dmrt1* [@pone.0071113-Krentz1], indicating that *Dmrt1* as a downstream target of TFAP2C cooperates in balancing pluripotency and germ cell differentiation. We conclude that TFAP2C represses the transcription of pluripotency-associated genes in PGCs.

During germ cell migration loss of global DNA-methylation is observed [@pone.0071113-HackettJ1]. Loss of DNA methylation in migrating PGCs occurs from approximately E8.0-- E11.5 [@pone.0071113-Sasaki1], [@pone.0071113-Seki2]. TFAP2C seems to contribute to this process by direct binding to regulatory regions and repression of the methyltransferases *Dnmt3b*, *Dnmt3l*, and *ubiquitin-like, containing PHD and RING finger domain 1* (*Uhrf1*). These genes are essential components of the *de novo* methylation machinery [@pone.0071113-Yamaji1], [@pone.0071113-Kurimoto2], [@pone.0071113-Bostick1], [@pone.0071113-Kato1]. After arrival at the genital ridges (E12.5), when *Tfap2c* is downregulated, the methylation levels are reinstalled [@pone.0071113-Liao1]. Interestingly, embryonal carcinomas display high levels of DNMT3B and DNMT3L [@pone.0071113-Skotheim1], [@pone.0071113-Sperger1], [@pone.0071113-Almstrup1], [@pone.0071113-Biermann1]. Hence, the failure to repress the *de novo* methylation indicates, that these cells are prone to transform to EC-like cells. There is an association between DNA methylation and GCC susceptibility due to the fact that the global loss of DNA methylation process overlaps with the critical period for GCC formation [@pone.0071113-Stevens2].

We demonstrated here that *Dmrt1* is a direct target gene of TFAP2C in PGCLCs. Interestingly, mice deficient for *Dmrt1* are sterile and 90% develop GCC [@pone.0071113-Krentz1]. A recent study by Krentz et al. investigated teratoma susceptibility in *Dmrt1^fl/fl^ : Nanos3^Cre/+^* male mice [@pone.0071113-Krentz2]. Interestingly, the authors found *Nanos3* haploinsufficiency to modify the susceptibility of *Dmrt1* deficient male mice by elevating the tumor incidence, clearly demonstrating a role of *Nanos3* in germ cell tumor development. However, in contrast to our results, the study of Krentz et al. could not demonstrate increased teratoma formation by *Nanos3* heterozygosity on its own. As discussed there, this fact could be due to insufficient outbreeding to the 129Sv genetic background. Further, 129S6/Sv : 129S1/Sv mice were used instead of 129S2/Sv as used in our study. Strain specific variation in tumor susceptibility may have an influence on the experimental outcome.

Mice deficient for *Pten* and *Dnd1* also display increased teratoma formation [@pone.0071113-Kimura1], [@pone.0071113-Youngren1], [@pone.0071113-Noguchi1]. Since, we did not see downregulation of these genes in *Tfap2c^−/−^*PGCLCs we hypothesize, that these genes act in different pathways. The observed upregulation of *Pten* in *Tfap2c^−/−^*PGCLCs is most likely due to induction of somatic differentiation, since *Pten* has been associated with development of neuronal and synaptic structures [@pone.0071113-Fraser1].

In *Tfap2c^+/−^* male gonads foci with cells displaying continued expression of pluripotency markers *Oct/4*, *Ssea1*, *Sox2* and *Nanog* were observed. In fact, this represents a hallmark critical for transformation of PGCs into embryonal carcinoma (EC) cells between E11.5--13.5 in mice [@pone.0071113-Stevens2]. Usually postmigratory PGCs downregulate pluripotency markers and enter mitotic arrest. However, EC cells show a block of germ cell differentiation and continued proliferation and expression of pluripotency markers also seen in human pediatric cancer.

In conclusion we provide evidence that the transcription factor TFAP2C orchestrates many aspects of the genetic network regulating germ cell development ([Fig. 6](#pone-0071113-g006){ref-type="fig"}). Maintenance and maturation of PGC are controlled by TFAP2C by repression of somatic differentiation, cell cycle, epigenetic remodeling, and pluripotency associated genes ([Fig. 6](#pone-0071113-g006){ref-type="fig"}). Furthermore, mice heterozygous for *Tfap2c* or its downstream target *Nanos3* display an increase in GCC susceptibility.

![Schematic of the genes and programs regulated by TFAP2C in primordial germ cells.\
Black arrows indicate pathways transactivated and induced by TFAP2C and black lines with terminal bars indicate pathways repressed by TFAP2C during development of primordial germ cells. Genes listed in respective pathways indicate direct regulation as demonstrated by ChIP analyses.](pone.0071113.g006){#pone-0071113-g006}
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###### 

**Generation of** ***Tfap2c^ctrl^*** **and** ***Tfap2c^−/−^*** **ESCs.** (A) Immunofluorescence staining against TFAP2C and SSEA1 protein in *ctrl* and *Tfap2c^−/−^*ESCs (cell line \#1 and \#2). Nuclei are stained with Hoechst. Scale bars: 100 µm. (B) Genotyping of *Blimp1mVenus/Tfap2c^flox/flox^* and *Blimp1mVenus/Tfap2c^−/−^* ESC lines by PCR. (C) FACS analysis to identify *Blimp1mVenus* positive PGCLCs. Population P3 showing *mVenus* positive cells. 8.1% *Blimp1mVenus* positive cells in ctrl whereas 3.2% positive cells measured in *Tfap2c^−/−^* cells.

(TIF)

###### 

Click here for additional data file.

###### 

***In vitro*** **differentiation of** ***Tfap2c^−/−^*** **and** ***ctrl*** **PGCLCs.** (A) Brightfield pictures of \#1-*ctrl* ESCs and after 1 and 2 days of *in vitro* differentiation into EpiLCs. EpiLCs show a flattened epithelial-like structure (A, middle). Scale bars: 100 µm (B) ESC and Epiblast markers were analysed by RT-PCR of RNA from \#1-*ctrl*; \#1-*Tfap2c^−/−^* and \#2-*ctrl*; \#2-*Tfap2c^−/−^* ESCs and EpiLCs. *β-Actin* served as control. (C) Brightfield pictures show \#1-*ctrl* and \#1-*Tfap2c^−/−^* EBs. PGCLC induction is indicated by *Blimp1mVenus* fluorescence. Scale bars: 100 µm (D) Graph showing the percentage and standard deviation of PGCLCs generation efficiency, measured by FACS for \#1-*ctrl* (9.3%) and \#2-*ctrl* (3%). Efficiency of PGCLC formation is lower in *Tfap2c^−/−^* cells (\#1∶2.7% and \#2∶1.5%). Significance **\*** *P*≤0.05. (E) RT-PCR from RNA of \#1-*ctrl*; \#1-*Tfap2c^−/−^* and \#2-*ctrl*; \#2-*Tfap2c^−/−^* PGCLCs. Expression of early germ cell markers (*Stella/Dppa3*, *Prdm14*, *Nanos3*) is reduced in *Tfap2c^−/−^*PGCLCs. As expected no signal was detected in *Tfap2c^−/−^*PGCLCs. *β-Actin* served as control.

(TIF)
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Deregulated genes in *Tfap2c^−/−^*PGCLCs (Fold-change \>1.5 in log2 scale).
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Deregulated genes in *Tfap2c^−/−^*ESCs (Fold-change \>1.5 in log2 scale).
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Commonly deregulated genes in *Tfap2c^−/−^*ESCs and -PGCLCs (Fold-change \>1.5 in log2 scale).
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Location of TFAP2/TFAP2C binding sites and primer sequences.
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Primer sequences for qRT-PCR.
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Gene Ontology analysis for \>1.5 fold-change in log2 scale for *Tfap2c^−/−^*PGCLCs in comparison to *ctrl* PGCLCs.
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